ArticleCancers2024
Incidence and Characteristics of Multiple Primary Cancers: A 20-Year Retrospective Study of a Single Cancer Center in Korea.
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Higher-order multiple primary cancers and persistent cross-site risk across human papillomavirus-related anatomical sites in the United States: a population-based Surveillance, Epidemiology, and End Results study.Preventive medicine reports · 2026Article
- Primary Lymphomas of the Female Genital Tract: Recognizing the Rare Mimicker of Gynecologic Malignancy.Medical sciences (Basel, Switzerland) · 2026Review
- Incidence Patterns and Prognostic Impact of Lung-Involving Multiple Primary Cancers: A 10-Year Hospital-Based Cohort Study.Thoracic cancer · 2026Article
- Subsequent primary cancer incidence among cancer survivors in the United States, 1975-2019: An age-period-cohort analysis.PLoS medicine · 2026Article
- Dual primary malignancies in Kashmir: A five-year analysis of temporal patterns, gender-specific presentations and treatment outcomes in a high gastrointestinal cancer risk population.Journal of family medicine and primary care · 2026Review
- The risk and prognosis factors of second primary malignancies in hepatocellular carcinoma survivors.Discover oncology · 2026Article
- Triple Synchronous Primary Malignant Tumors of the Liver, Kidney, and Lung in a Male Patient: Case Report and Systematic Review.Diagnostics (Basel, Switzerland) · 2025Article
- Multiple primary cancers with prostate malignant tumor as the initial diagnosis: a case report.Discover oncology · 2025Article
- A clinical report and analysis of metachronous multiple primary cancers occurred in four sites.Journal of cancer research and clinical oncology · 2025Article
- Multiple Primary Cancers as an Independent Criterion for Germline Testing: Comparison with Guideline-Based Criteria.Journal of clinical medicine · 2025Article
- Article
- Case report: surgery combined with a SOX adjuvant chemotherapy regimen for patients with gastric adenocarcinoma and hepatocellular carcinoma.American journal of translational research · 2025Article
- Early death prediction model for breast cancer with synchronous lung metastases: an analysis of the SEER database.Gland surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Rising cancer survival rates have led to an increased risk of multiple primary cancers (MPCs). Data on MPCs in South Korea are limited. This study aimed to address incidence and clinical characteristics of MPCs in a single cancer center in Korea during a 20-year period. We retrospectively analyzed 96,174 cancer patients at the Korea Cancer Center Hospital between 2003 and 2022, identifying 2167 patients with metachronous MPCs based on Surveillance, Epidemiology, and End Results SEER criteria. We categorized patients by cancer type (15 major solid cancer groups and 3 major hematologic cancer groups), including pathological diagnosis, assessed latency periods, and relative risks (RRs) for developing MPCs. The overall MPC incidence was 2.3%. Breast cancer (15.7%) was the most common primary cancer, and lung cancer (15.2%) was the most frequent second primary cancer. The median latency period for second primary cancers was 4.1 years. Decreasing latency periods for third and fourth primary cancers were observed (2.1 years and 1.6 years, respectively). Most cancers maintained their dominant pathological type despite notable changes in the prevalence of specific pathologies for certain types of second primaries. Lymphoma showed the highest RR (2.1) for developing MPCs. Significant associations were found between specific primary and subsequent cancers, including breast-ovary, thyroid-breast, stomach-pancreas, colorectal-head and neck, lung-prostate, and lymphoma-myeloid neoplasms. These findings contribute to a better understanding of MPC occurrence. They can inform future research on their etiology and development of improved management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.